Researchers conducted a study to determine whether the TAK-003 vaccine effectively protects against dengue fever in children and adolescents for up to 3 years.
Study authors searched medical databases to identify factors that could be detected in the febrile phase associated with progression to severe dengue disease.
A high frequency of climate-change associated severe weather events have created an increased human-to-human transmission risk for novel diseases.
Confirmation of an 11th case of dengue fever in the Florida Keys.
The CDC has summarized present and updated guidelines on dengue and Zika virus diagnostic testing in patients with a clinically compatible illness who live in or recently traveled to an endemic area.
The TIDES trial is investigating the safety and efficacy of 2 doses of TAK-003 in preventing dengue fever caused by any of the 4 dengue virus serotypes.
Two Phase 3 trials conducted in Asia and Latin America assessed the efficacy of the vaccine in >35,000 individuals aged 2 to 16 years.
The failure mode and effect analysis methodology may facilitate protocols for new control that would benefit dengue detection and assessment for the 2020 Olympics.
The principles of “trolleyology” can be used to understand hesitancy among certain individuals to vaccinate against the Dengue virus.
Diagnostic indicators including conjunctivitis, platelet count, and monocyte count can be used to reliably distinguish between Zika virus and dengue fever.
